APVO - Aptevo Therapeutics Inc Stock Price, Fair Value and News

0.81USD+0.01 (+1.25%)Delayed

Market Summary

USD0.81+0.01

Delayed

1.25%

APVO Stock Price

View Fullscreen

APVO RSI Chart

APVO Valuation

Market Cap

3.3M

Price/Earnings (Trailing)

-0.12

Price/Sales (Trailing)

1.17

EV/EBITDA

0.1

Price/Free Cashflow

-0.14

APVO Price/Sales (Trailing)

APVO Profitability

EBT Margin

-1666.57%

Return on Equity

-442.71%

Return on Assets

-153.26%

Free Cashflow Yield

-694.32%

APVO Fundamentals

APVO Revenue

Revenue (TTM)

3.1M

APVO Earnings

Earnings (TTM)

-27.0M

Earnings Growth (Yr)

-346.45%

Earnings Growth (Qtr)

-15.78%

Breaking Down APVO Revenue

Last 7 days

-9.0%

Last 30 days

14.1%

Last 90 days

-88.0%

Trailing 12 Months

-98.9%

How does APVO drawdown profile look like?

APVO Financial Health

Current Ratio

1.92

Debt/Equity

0.24

Debt/Cashflow

-15.76

APVO Investor Care

Shares Dilution (1Y)

2362.61%

Diluted EPS (TTM)

-90.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	13.0M	37.7M	20.4M	3.1M
2021	6.8M	9.4M	11.0M	12.3M
2020	0	23.1M	13.7M	4.3M
2019	26.0M	26.6M	29.7M	32.4M
2018	16.6M	19.9M	19.5M	23.1M
2017	23.9M	17.3M	20.6M	14.7M
2016	30.0M	33.1M	29.4M	29.8M
2015	0	0	0	33.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aptevo Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	taylor daphne	acquired	-	-	1,584	svp, cfo
Mar 03, 2024	white marvin l	acquired	-	-	9,584	president and ceo
Mar 03, 2024	lamothe jeffrey g.	acquired	-	-	3,667	evp, coo
Mar 03, 2024	kwon soyoung	acquired	-	-	3,667	svp, gc, bd & corp affairs
Mar 02, 2024	taylor daphne	acquired	-	-	3,667	svp, cfo
Mar 02, 2024	white marvin l	acquired	-	-	12,917	president and ceo
Mar 02, 2024	lamothe jeffrey g.	acquired	-	-	5,500	evp, coo
Mar 02, 2024	kwon soyoung	acquired	-	-	3,667	svp, gc, bd & corp affairs
Jan 29, 2024	taylor daphne	acquired	-	-	792	svp, cfo
Jan 28, 2024	white marvin l	acquired	-	-	4,792	president and ceo

Which funds bought or sold APVO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	sold off	-100	-1,980	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-47,444	-	-%
May 15, 2024	CANTOR FITZGERALD, L. P.	sold off	-100	-10,594	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-18,934	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-2,036	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	6,209	6,209	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-2,472	-	-%
May 15, 2024	SABBY MANAGEMENT, LLC	sold off	-100	-63,254,000	-	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-11,065	-	-%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-25,104	-	-%

Are Funds Buying or Selling APVO?

Are funds buying APVO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own APVO

No. of Funds

Unveiling Aptevo Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	1,731,034	SC 13G
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Nov 26, 2021	tang capital partners lp	0.0%	0	SC 13D/A
Nov 22, 2021	tang capital partners lp	18.8%	921,336	SC 13D/A
Jun 21, 2021	tang capital partners lp	39.6%	1,760,000	SC 13D/A
Feb 16, 2021	point72 asset management, l.p.	0%	0	SC 13G/A
Feb 16, 2021	armistice capital, llc	0%	0	SC 13G/A
Feb 12, 2021	rtw investments, lp	6.96%	288,236	SC 13G/A
Feb 12, 2021	stonepine capital management, llc	0.4%	18,280	SC 13G/A
Feb 11, 2021	renaissance technologies llc	5.81%	254,423	SC 13G/A

Recent SEC filings of Aptevo Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 15, 2024	8-K	Current Report
Apr 12, 2024	424B4	Prospectus Filed
Apr 10, 2024	EFFECT	EFFECT
Apr 09, 2024	S-1/A	Initial Public Offering
Apr 08, 2024	CORRESP	CORRESP

Peers (Alternatives to Aptevo Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Aptevo Therapeutics Inc News

Latest updates

Aptevo Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-100.0%	-	1,827,000	10,505,000	19,183,000	27,861,000	3,114,000	3,665,000	3,096,000	3,110,000	2,421,000	2,373,000	1,463,000	5,247,000	9,031,000	9,011,000	7,360,000	7,022,000	6,346,000	5,824,000	6,826,000	4,071,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	7,280,000	-	-	10,404,000	11,162,000	-	-	-	-
S&GA Expenses	-100.0%	-	3,588,000	3,010,000	3,307,000	3,697,000	3,859,000	3,162,000	3,479,000	4,110,000	3,947,000	4,280,000	3,215,000	2,840,000	3,528,500	3,863,000	4,279,000	4,528,000	6,577,500	6,940,000	7,023,000	7,592,000
R&D Expenses	-10.0%	3,752,000	4,168,000	4,674,000	4,477,000	3,865,000	4,866,000	4,543,000	4,367,000	4,722,000	5,362,000	4,912,000	4,494,000	4,440,000	4,408,000	7,596,000	6,125,000	6,634,000	8,899,000	8,574,000	9,713,000	-
EBITDA Margin	-0.7%	-16.51	-16.40	-16.38	-2.49	-1.35	-3.91	-4.13	-4.61	-5.41	-7.41	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-999,000	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-6,948,000	-	-	-12,084,000	-	-	-14,096,000	-12,562,000	-13,155,000	-13,908,000
EBT Margin	0%	-16.67	-16.67	-16.67	-2.54	-1.38	-4.00	-4.22	-4.72	-5.54	-7.59	-	-	-	-	-	-	-	-	-	-	-
Net Income	-346.4%	-6,834,000	2,773,000	-4,642,000	-7,644,000	28,010,000	-7,697,000	-6,272,000	-6,997,000	-7,932,000	-7,256,000	-7,053,000	-6,791,000	-6,803,000	-8,174,000	-6,924,000	-13,332,000	-12,018,000	-14,128,500	-12,562,000	-13,144,000	-
Net Income Margin	-246.1%	-8.68	5.94	2.58	0.31	0.19	-2.23	-2.32	-2.66	-3.10	-4.08	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-245.7%	-6,651,000	4,566,000	-5,939,000	-6,900,000	-3,188,000	-5,235,000	-3,998,000	-5,255,000	-5,444,000	-7,695,000	-6,123,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-29.0%	17,629	24,842	27,129	28,912	34,969	34,215	31,695	38,799	45,184	56,601	64,005	71,474	68,753	53,547	37,420	18,509	25,244	53,408	60,556	66,127	80,841
Current Assets	-36.7%	12,074	19,066	21,126	22,680	28,485	27,450	24,618	31,400	41,672	52,570	58,873	65,765	62,850	47,264	30,653	10,488	14,825	29,995	36,789	43,672	57,642
Cash Equivalents	-39.4%	10,250	16,904	19,110	21,006	25,328	22,635	22,150	29,431	34,991	45,044	52,118	60,394	57,524	39,979	24,942	7,599	12,258	12,448	17,683	20,957	37,011
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,139	7,482	6,967	4,346
Net PPE	-11.8%	789	895	1,011	1,134	1,284	1,462	1,669	1,887	2,138	2,379	2,521	2,804	2,712	2,815	3,020	3,320	3,629	3,946	4,271	4,610	4,978
Liabilities	-8.7%	11,526	12,621	12,411	12,659	11,713	16,241	15,933	15,752	51,068	55,385	56,713	57,593	58,249	36,953	35,218	9,859	10,092	41,566	40,811	39,928	41,711
Current Liabilities	-12.8%	6,298	7,224	6,836	6,911	5,797	8,706	7,786	7,003	23,857	34,757	32,380	30,864	29,344	14,539	7,417	7,002	6,993	38,239	37,252	16,598	18,290
Long Term Debt	-	-	-	-	-	-	1,456	1,910	-	-	3,707	-	-	-	-	-	-	-	-	-	19,558	19,415
LT Debt, Current	-	-	-	-	-	-	2,000	2,000	2,000	2,000	11,667	11,167	10,667	10,167	5,000	-	-	-	19,863	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	1,456	1,910	-	-	3,707	-	-	-	-	-	-	-	-	-	19,558	19,415
Shareholder's Equity	-50.1%	6,103	12,221	14,718	16,253	23,256	17,974	15,762	23,047	-	1,216	7,292	13,881	10,504	16,594	2,202	8,650	15,152	11,842	19,745	26,199	39,130
Retained Earnings	-3.1%	-230,281	-223,447	-217,545	-211,211	-203,263	-206,036	-201,394	-193,750	-221,760	-214,063	-207,791	-200,794	-192,862	-185,606	-178,553	-171,762	-164,959	-167,856	-159,682	-152,758	-139,426
Additional Paid-In Capital	0.3%	236,318	235,607	232,207	227,415	226,470	223,962	217,109	216,750	215,829	215,232	215,036	214,628	203,320	202,154	180,710	180,367	180,066	179,653	179,382	178,912	178,511
Shares Outstanding	52.2%	673	442	329	171	165	147	116	113	112	111	105	103	100	-	-	-	-	-	-	-	-
Float	-	-	-	-	11,000	-	-	-	18,000	-	-	-	93,100	-	-	-	24,100	-	-	-	36,600	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-26.6%	-6,651	-5,253	-6,240	-4,803	4,566	-5,939	-6,896	-3,070	-5,117	-3,880	-5,242	-5,053	-7,504	-6,123	-7,387	-4,633	-11,175	-5,100	-7,548	-15,891	-13,844
Share Based Compensation	100.8%	719	358	455	465	915	357	359	485	601	178	319	572	574	198	343	301	413	269	334	401	594
Cashflow From Investing	-	-	-	-	-	-	-	-4.00	-	-	-118	-13.00	-391	-191	-88.00	-	-	28,120	-	4,250	-	-153
Cashflow From Financing	-100.1%	-3.00	3,046	4,344	481	-1,873	5,998	-500	-3,178	-4,936	-3,076	-3,021	8,316	23,942	21,248	24,730	-	-22,104	-135	24.00	-113	20,373

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

APVO Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ (3,752,000)	$ (4,168,000)
General and administrative	(3,231,000)	(3,588,000)
Loss from operations	(6,983,000)	(7,756,000)
Other income (expense):
Other income (expense) from continuing operations, net	149,000	(67,000)
Gain related to sale of non-financial asset		9,650,000
Net (loss) income from continuing operations	(6,834,000)	1,827,000
Discontinued operations:
Income from discontinued operations	0	946,000
Net (loss) income	$ (6,834,000)	$ 2,773,000
Basic and diluted net (loss) income per share from continuing operations:
Basic	$ (9.95)	$ 11.45
Diluted	(9.95)	11.45
Basic net (loss) income per share	(9.95)	17.38
Diluted net (loss) income per share	$ (9.95)	$ 17.38
Shares used in calculation:
Basic shares used in calculation	686,735	159,597
Diluted shares used in calculation	686,735	159,597

APVO Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 10,250	$ 16,904
Prepaid expenses	1,133	1,473
Other current assets	691	689
Total current assets	12,074	19,066
Property and equipment, net	789	895
Operating lease right-of-use asset	4,766	4,881
Total assets	17,629	24,842
Current liabilities:
Accounts payable and other accrued liabilities	3,720	3,984
Accrued compensation	1,610	2,098
Other current liabilities	968	1,142
Total current liabilities	6,298	7,224
Other long-term liabilities	14
Operating lease liability	5,214	5,397
Total liabilities	11,526	12,621
Stockholders' equity:
Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding
Common stock: $0.001 par value; 500,000,000 shares authorized; 673,430 and 442,458 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	66	61
Additional paid-in capital	236,318	235,607
Accumulated deficit	(230,281)	(223,447)
Total stockholders' equity	6,103	12,221
Total liabilities and stockholders' equity	$ 17,629	$ 24,842

About Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

CEO	Mr. Marvin L. White
WEBSITE	aptevotherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	45

Aptevo Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aptevo Therapeutics Inc? What does APVO stand for in stocks?

APVO is the stock ticker symbol of Aptevo Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aptevo Therapeutics Inc (APVO)?

As of Fri May 17 2024, market cap of Aptevo Therapeutics Inc is 3.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APVO stock?

You can check APVO's fair value in chart for subscribers.

What is the fair value of APVO stock?

You can check APVO's fair value in chart for subscribers. The fair value of Aptevo Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aptevo Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APVO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aptevo Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether APVO is over valued or under valued. Whether Aptevo Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aptevo Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APVO.

What is Aptevo Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, APVO's PE ratio (Price to Earnings) is -0.12 and Price to Sales (PS) ratio is 1.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APVO PE ratio will change depending on the future growth rate expectations of investors.